Navigation Links
Hospira Reports Fourth-Quarter and Full-Year 2012 Results
Date:2/13/2013

ompany's quality-related actions and the impact of foreign exchange.

Adjusted* income from operations decreased 31.9 percent to $456 million for the full year of 2012, compared to $669 million for the full year of 2011. The decrease primarily reflects the full-year impact of higher manufacturing expense associated with the company's quality-related actions, which were accelerated beginning in the third quarter of 2011. In addition, in 2012 the company incurred higher biosimilar clinical spending, as well as higher selling and promotional costs, primarily related to supporting Precedex. On a GAAP basis, full-year 2012 income from operations was $59 million compared to $57 million; affecting the year-over-year comparison was the impact in 2011 of goodwill impairment charges, as well as the impact in 2012 of higher continuous improvement charges and quality-and product-related charges.

The full-year 2012 effective tax rate on an adjusted basis* was an expense of 18.3 percent compared to an expense of 20.5 percent in 2011. On a GAAP basis, the 2012 effective tax rate was a benefit of 121.7 percent compared to an expense of 103.0 percent in 2011. The 2012 effective tax rate on a GAAP basis was impacted by certain quality, impairment and restructuring charges incurred in higher-tax-rate jurisdictions, partially offset by an expense related to the effective settlement of a U.S. federal tax audit.

Cash Flow Cash flow from operations for full-year 2012 was $478 million, compared to $434 million in 2011. The majority of the increase reflects lower working capital investments in 2012, which more than offset higher operating expenses.

Capital expenditures were $290 million for full-year 2012 compared to $291 million in 2011.

2013 Projections Hospira expects net sales growth for full-year 2013 to be in a range of 1 to 3 percent on both a constant-currency and reported basis.

Adjusted* diluted earnings per share for 2013 are expected to
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Hospira to Present at Upcoming Investor Conferences
2. Hospira and Q Core Medical Sign International Distribution Agreement for Sapphire Infusion System
3. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
4. Hospira Reports Third-Quarter 2012 Results
5. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
6. Hospira Reports Second-Quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira to Host Conference Call for Second-quarter 2012 Results
9. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
10. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
11. Hospira to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, ... company, today announced that the Food and Drug Administration ... provide comments on RCP,s Investigational New Drug ("IND") application ... trial in the US. Dr. Chris ... review and comments on our IND. When we receive ...
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed ... diagnosed incident cases in 2013 to 11,568 diagnosed incident ... of 4.35%, during the forecast period. In 2023, the ... cases of aGVHD in the 6MM, with 4,989 diagnosed ... of diagnosed incident cases of aGVHD, with 704 diagnosed ...
(Date:7/13/2014)... 2014 A decreased ability to identify odors ... Alzheimer,s disease, while examinations of the eye could ... with Alzheimer,s, in the brain, according to the ... the Alzheimer,s Association International Conference 2014 (AAIC 2014) ... the decreased ability to identify odors was significantly ...
(Date:7/13/2014)... Wright & Schulte LLC has learned that ... July of 2015, in U.S. District Court, District of ... discovery process in the South Carolina federal court ... the multidistrict litigation (MDL). The complaints pending in the ... allege that they took the statin medication to lower ...
(Date:7/13/2014)... Celebrity fitness trainer and former World Super ... with Aqua Health Labs for their flagship product PhytOriginal, ... The collaboration was recently announced live on ESPN Radio. ... actor, model, and a two time World Super Middleweight ... has prepared stars including Demi Moore, Hilary Swank and ...
(Date:7/13/2014)... Palatine, Illinois (PRWEB) July 13, 2014 Hope ... facilitating a monthly grief support group at the Tamarack Senior ... will be held at 10:30 A.M. on the 3rd Wednesdays ... July 16th, 2014 at the Tamarack Community located at 55 ... to all bereaved individuals and there is no cost for ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... known that HIV patients are at an increased risk of ... shows // aggressive antiretroviral therapy may help lower that risk. ... therapy was associated with a lower incidence of Kaposi sarcoma ... more than 7,300 patients infected with HIV and the data ...
... In a study published in Diabetes Care, March 2005, scientists ... ,Insulin sensitivity is the measure for the risk ... then he has a lower risk of heart problems. ... insulin to control blood sugar. As this happens the body ...
... and heart attack can be reduced for heart patients undergoing ... of an anti-clotting drug before the procedure is the answer.// ... catheter is threaded into an artery. The balloon is inflated ... A small synthetic tube - stent is used to hold ...
... is known to help in controlling obesity. A new study ... Obesity (2005) says that dietary calcium present in the yogurt ... in lipid utilization and decrease in lipogenesis. ... one group was put on balanced deficit diets and the ...
... standard treatment with levodopa can reduce the amount of ... fluctuations they experience during the day . ,For ... drug entacapone, which must be taken with every levodopa ... of the additional drugs were effective in reducing the ...
... being hailed by researchers for its ability to target cancer ... called ON01910 works by interfering with a molecule known as ... multiply. This molecule is found in higher numbers in cancerous ... have especially high amounts. ,The drug was tested ...
Cached Medicine News:
The Uromac Petite data processor, transducers and Powerbook® computer can be disassembled quickly and easily for travel to multiple sites, providing a very flexible and portable urodynamics syste...
... by Laborie, a leading producer ... credible tracings. ICS recognized Urodynamics ... parameters. Designed especially for the ... to be quick, efficient and ...
... The wireless TRITON™ offers ultimate flexibility ... of the computer, printer and display. Wall-mount ... wireless system by choosing a laptop, touch ... Incorporating the latest technology, this multi-function patient ...
... Advanced diagnostic capabilities combined with ease of ... product in its class. Ideal for office ... complete system for Uroflowmetry, cystometry, leak point ... configurations are available which make the OM-5 ...
Medicine Products: